Her2 (ERBB2) Mouse Monoclonal Antibody [Clone ID: UMAB35]

CAT#: UM570035

Purified HER2 (ERBB2) mouse monoclonal antibody,clone UMAB35

Product Images

OriGene overexpression protein microarray chip was immunostained with UltraMAB anti-ERBB2 mouse monoclonal antibody (Clone UMAB35). The positive reactive proteins are highlighted with two red arrows in the enlarged subarray. All the positive controls spotted in this subarray are also labeled for clarification. These data show that UltraMAB anti-ERBB2 (Clone UMAB35) very specifically recognizes ERBB2 antigen on OriGene protein microarray chip.

• 

  Western blot analysis of cell lysates of HEK293 transfected with ERBB2 cDNA (Left lane) or untransfected (Right lane) by using ERBB2 UltraMAB (UM500035, clone UMAB35, 1:500).

• 

  Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-ERBB2 monoclonal antibody (Clone UMAB35) at 1:500.

• 

  Anti-ERBB2 mouse monoclonal antibody (UM500035, clone UMAB35, 1:100) immunofluorescent staining of MCF7 cells.

• 

  Anti-ERBB2 mouse monoclonal antibody (UM500035, clone UMAB35, 1:100) immunofluorescent staining of COLO205 cells.

• 

  Western blot of cell lysates (35ug) from 9 different cell lines (1: HepG2, 2: HeLa, 3: SV-T2, 4: A549, 5: COS7, 6: Jurkat, 7: MDCK, 8: PC-12, 9: MCF7). Diluation: 1:500

• Western blot of mouse tissue lysates (20ug) from Uterus. Primary antibody diluation: 1:500. Secondary antibody dilution: Mouse TrueBlot® Ultra (1:1000).

• Immunohistochemical staining of paraffin-embedded Carcinoma of bladder tissue using anti-ERBB2mouse monoclonal antibody. (Clone UMAB35, dilution 1:100; heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120°C for 3min)

Show all 8 images

Specifications

Product Data

• Clone Name: UMAB35
• Applications: 10k-ChIP, IF, IHC, WB
• Recommended Dilution: WB:1:500, IHC:1:50, IF:1:100
• Reactivities: Human, Mouse, Rat, Dog
• Host: Mouse
• Isotype: IgG2b
• Clonality: Monoclonal
• Immunogen: Human recombinant protein fragment corresponding to amino acids 676-1255 of human ERBB2(NP_004439) produced in HEK293T cell.
• Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
• Concentration: 0.5~1.0 mg/ml (Lot Dependent)
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Predicted Protein Size: 137.7 kDa
• Gene Name: Homo sapiens erb-b2 receptor tyrosine kinase 2 (ERBB2), transcript variant 1, mRNA.
• Database Link:
  NP_004439
  Entrez Gene 13866 MouseEntrez Gene 24337 RatEntrez Gene 403883 DogEntrez Gene 2064 Human
  UniProt ID P04626
• Background: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
• Synonyms: CD340; HER-2; HER2; MLN 19; NEU; neu; NGL; TKR1

Reference Data

• Protein Families: Druggable Genome, Protein Kinase, Transmembrane
• Protein Pathways: Adherens junction, Bladder cancer, Calcium signaling pathway, Endometrial cancer, ErbB signaling pathway, Focal adhesion, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Prostate cancer